Jiangsu Lanfeng Bio-chemical Co.,Ltd (SHE:002513)
China · Delayed Price · Currency is CNY 6.51
+0.07 (1.09%)
Apr 30, 2026, 3:04 PM CST
SHE:002513 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,330 | 1,765 | 1,702 | 1,444 | 1,438 |
Other Revenue | 12.39 | 27.86 | 39.33 | 1.61 | 5.58 |
| 2,342 | 1,793 | 1,742 | 1,445 | 1,444 | |
Revenue Growth (YoY) | 30.61% | 2.96% | 20.51% | 0.09% | 7.60% |
Cost of Revenue | 2,287 | 1,901 | 1,805 | 1,452 | 1,473 |
Gross Profit | 54.98 | -107.56 | -63.2 | -7.12 | -29.22 |
Selling, General & Admin | 147.5 | 129.92 | 166.7 | 103.69 | 149.85 |
Research & Development | 63.13 | 68.68 | 15.26 | 11.65 | 12.92 |
Other Operating Expenses | 2.12 | 3.9 | 4.94 | 5.76 | 6.24 |
Operating Expenses | 216.17 | 212.92 | 194.57 | 121.51 | 194.61 |
Operating Income | -161.19 | -320.48 | -257.78 | -128.63 | -223.83 |
Interest Expense | -53.54 | -59.53 | -26.53 | -13.55 | -22.6 |
Interest & Investment Income | 9.23 | 8.18 | 32.63 | 10.07 | 4.02 |
Currency Exchange Gain (Loss) | 1.6 | 7.78 | 1.65 | 2.75 | -2.1 |
Other Non Operating Income (Expenses) | -20.66 | -44.26 | -6.23 | -54.89 | -6.3 |
EBT Excluding Unusual Items | -224.56 | -408.32 | -256.26 | -184.26 | -250.8 |
Gain (Loss) on Sale of Assets | -0.49 | -0.36 | -1.46 | 1.47 | -1.92 |
Asset Writedown | -62.78 | - | -92.61 | - | -291.5 |
Other Unusual Items | -2.24 | -26.32 | -4 | -64.18 | 5.37 |
Pretax Income | -290.07 | -434.84 | -354.33 | -246.97 | -538.86 |
Income Tax Expense | -18.29 | -81.61 | -6.6 | 73.72 | -47.67 |
Earnings From Continuing Operations | -271.78 | -353.23 | -347.74 | -320.69 | -491.19 |
Minority Interest in Earnings | 81.26 | 100.73 | 15.48 | 0 | - |
Net Income | -190.53 | -252.5 | -332.26 | -320.69 | -491.19 |
Net Income to Common | -190.53 | -252.5 | -332.26 | -320.69 | -491.19 |
Shares Outstanding (Basic) | 375 | 369 | 373 | 374 | 341 |
Shares Outstanding (Diluted) | 375 | 369 | 373 | 374 | 341 |
Shares Change (YoY) | 1.79% | -1.13% | -0.29% | 9.63% | -7.96% |
EPS (Basic) | -0.51 | -0.68 | -0.89 | -0.86 | -1.44 |
EPS (Diluted) | -0.51 | -0.68 | -0.89 | -0.86 | -1.44 |
Free Cash Flow | -520.91 | -171.06 | -851.66 | -95.43 | -77.08 |
Free Cash Flow Per Share | -1.39 | -0.46 | -2.28 | -0.26 | -0.23 |
Gross Margin | 2.35% | -6.00% | -3.63% | -0.49% | -2.02% |
Operating Margin | -6.88% | -17.87% | -14.80% | -8.90% | -15.50% |
Profit Margin | -8.13% | -14.08% | -19.08% | -22.19% | -34.02% |
Free Cash Flow Margin | -22.24% | -9.54% | -48.90% | -6.60% | -5.34% |
EBITDA | -23.45 | -198.27 | -160.01 | -33.4 | -107.55 |
EBITDA Margin | -1.00% | -11.06% | -9.19% | -2.31% | -7.45% |
D&A For EBITDA | 137.73 | 122.21 | 97.77 | 95.24 | 116.28 |
EBIT | -161.19 | -320.48 | -257.78 | -128.63 | -223.83 |
EBIT Margin | -6.88% | -17.87% | -14.80% | -8.90% | -15.50% |
Revenue as Reported | 2,342 | 1,793 | 1,742 | 1,445 | 1,444 |
Advertising Expenses | 8.18 | 8.56 | 4.79 | 2.03 | 0.28 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.